Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luisa M Stamm

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
Microbes and Infection|December 15, 2004
Mycobacterium marinum: the generalization and specialization of a pathogenic mycobacteriumLuisa M Stamm, Eric J Brown
Science (New York, N.Y.)|March 10, 2011
Microbiology. Establishing the secretion hierarchyLuisa M Stamm, Marcia B Goldberg
Cell Host & Microbe|November 16, 2010
Caging targets for destructionLuisa M Stamm, Danielle M Heller, Marcia B Goldberg
Journal of Hepatology|November 17, 2018
Sofosbuvir/velpatasvir for patients with chronic genotype 3 HCV infection with compensated cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018Luisa M Stamm, Diana M Brainard, John G McHutchison
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 10, 2018
Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 TrialSarah E Kleinstein, Patrick R Shea, Luisa M Stamm, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 10, 2018
Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy VolunteersErik Mogalian, Luisa M Stamm, Anu Osinusi, et al.
The American Journal of Medicine|October 16, 2012
Acute nonrheumatic streptococcal myocarditis: STEMI mimic in young adultsGaurav A Upadhyay, Justin F Gainor, Luisa M Stamm, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 4, 2005
Role of the WASP family proteins for Mycobacterium marinum actin tail formationLuisa M Stamm, Melissa A Pak, J Hiroshi Morisaki, et al.
Hepatology (Baltimore, Md.)|July 7, 2015
Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infectionAaron F Carlin, Paula Aristizabal, Qinghua Song, et al.
Gastroenterology|February 1, 2017
Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 InfectionEdward J Gane, Robert H Hyland, Yin Yang, et al.
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Microbes and Infection|December 15, 2004
Mycobacterium marinum: the generalization and specialization of a pathogenic mycobacteriumLuisa M Stamm, Eric J Brown
Science (New York, N.Y.)|March 10, 2011
Microbiology. Establishing the secretion hierarchyLuisa M Stamm, Marcia B Goldberg
Cell Host & Microbe|November 16, 2010
Caging targets for destructionLuisa M Stamm, Danielle M Heller, Marcia B Goldberg
Journal of Hepatology|November 17, 2018
Sofosbuvir/velpatasvir for patients with chronic genotype 3 HCV infection with compensated cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018Luisa M Stamm, Diana M Brainard, John G McHutchison
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 10, 2018
Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 TrialSarah E Kleinstein, Patrick R Shea, Luisa M Stamm, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 10, 2018
Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy VolunteersErik Mogalian, Luisa M Stamm, Anu Osinusi, et al.
The American Journal of Medicine|October 16, 2012
Acute nonrheumatic streptococcal myocarditis: STEMI mimic in young adultsGaurav A Upadhyay, Justin F Gainor, Luisa M Stamm, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 4, 2005
Role of the WASP family proteins for Mycobacterium marinum actin tail formationLuisa M Stamm, Melissa A Pak, J Hiroshi Morisaki, et al.
Hepatology (Baltimore, Md.)|July 7, 2015
Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infectionAaron F Carlin, Paula Aristizabal, Qinghua Song, et al.
Gastroenterology|February 1, 2017
Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 InfectionEdward J Gane, Robert H Hyland, Yin Yang, et al.
Pageof 5